On December 2-3, the 2022 China Health Industry Innovation Summit and the 4th "CHIP Award" award ceremony was held in Shanghai and the "CHIP Seed List" was announced. Hopstem's iPSC cell therapy product development platform project won the "2022 Drug Innovation CHIP Seed TOP10".

The projects of companies on the list need to address unmet clinical needs, have original and differentiated innovations, and have bright prospects for commercialization. Since the launch of the first "CHIP Seeds" list, it has received widespread attention and positive responses from people in the health industry across the country. After rigorous screening by the review team, Hopstem was honored to be on the list. It reflects the medical and health industry's high recognition of Hopstem's development potential in the field of pharmaceutical innovation and iPSC cell therapy product development platform.